13.89
1.40 (11.21%)
| Previous Close | 12.49 |
| Open | 12.72 |
| Volume | 130,444 |
| Avg. Volume (3M) | 91,459 |
| Market Cap | 369,375,488 |
| Price / Sales | 6.52 |
| Price / Book | 2.73 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -76.05% |
| Operating Margin (TTM) | -56.13% |
| Diluted EPS (TTM) | -0.970 |
| Quarterly Revenue Growth (YOY) | 100.30% |
| Total Debt/Equity (MRQ) | 53.19% |
| Current Ratio (MRQ) | 6.48 |
| Operating Cash Flow (TTM) | -26.21 M |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Mixed | Bearish |
| Health Information Services (Global) | Mixed | Bearish | |
| Stock | Carlsmed, Inc. | Bullish | - |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.13 |
|
Carlsmed Inc is a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. It is focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of AI-enabled software solutions, and interbody implants that it custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments. The Company designs, manufactures, and markets aprevo, a comprehensive technology platform for spine fusion surgery procedures. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| % Held by Insiders | 4.06% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Burkehill Global Management, Lp | 30 Sep 2025 | 50,000 |
| 52 Weeks Range | ||
| Median | 24.00 (72.79%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 15 Dec 2025 | 24.00 (72.79%) | Buy | 12.91 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025 |
| 06 Jan 2026 | Announcement | Carlsmed aprevo® Lumbar 2-year Data Published in Global Spine Journal |
| 16 Dec 2025 | Announcement | Carlsmed, Inc. To Participate in the J.P. Morgan 2026 Healthcare Conference |
| 03 Dec 2025 | Announcement | Carlsmed Announces U.S. Launch of its aprevo® Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |